Compare Thomson Reuters Corp (TRI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Thomson Reuters Corp vs Twist Bioscience Corp — how do they compare? Thomson Reuters Corp trades at $100.95 (market cap $43.21B), while Twist Bioscience Corp trades at $158.2 (market cap $10.32B). The key difference: Thomson Reuters Corp is far larger — about 4.2× Twist Bioscience Corp's market cap, and Thomson Reuters Corp pays a 2.64% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Thomson Reuters Corp for 63 Days and Twist Bioscience Corp for 27 Days on average.
| TRI | TWST | |
|---|---|---|
Market Cap | $43.21B | $10.32B |
Volume | 1,017,653 | 5,894,998 |
Sector | Industrials | Health |
52-Week High | $163.45 | $205.00 |
52-Week Low | $76.55 | $25.45 |
Typical Hold Time | 63 Days | 27 Days |
Enterprise Value | $45.82B | $10.24B |
Dividend Yield | 2.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Thomson Reuters (TRI) stock trades at $101.55, up 3.53% today, showing strong momentum amid positive technical signals and fundamental strength. The company demonstrates robust profitability with 75.7% gross margins and 21.22% net income margins, supported by 10% organic growth in core businesses. Recent developments include the successful divestment of its printing unit and the launch of proprietary AI technology, positioning TRI for continued growth in the legal and professional information markets.
With analyst consensus pointing to 31% upside to the $133.25 price target and strong institutional buying, TRI presents a compelling growth opportunity. However, investors should monitor execution risks around AI integration and potential cybersecurity vulnerabilities following recent incidents. The stock's current valuation at 26.16x P/E appears reasonable given the company's recurring revenue model and market leadership position.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
